Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Asset Writedowns and Impairment (2023 - 2025)

Historic Asset Writedowns and Impairment for 10x Genomics (TXG) over the last 3 years, with Q3 2025 value amounting to $700000.0.

  • 10x Genomics' Asset Writedowns and Impairment changed N/A to $700000.0 in Q3 2025 from the same period last year, while for Dec 2025 it was $814000.0, marking a year-over-year decrease of 7334.64%. This contributed to the annual value of $814000.0 for FY2025, which is 7334.64% down from last year.
  • 10x Genomics' Asset Writedowns and Impairment amounted to $700000.0 in Q3 2025.
  • In the past 5 years, 10x Genomics' Asset Writedowns and Impairment ranged from a high of $7.1 million in Q4 2023 and a low of $114000.0 during Q1 2025
  • Its 3-year average for Asset Writedowns and Impairment is $2.3 million, with a median of $1.6 million in 2024.
  • In the last 5 years, 10x Genomics' Asset Writedowns and Impairment crashed by 9150.14% in 2024 and then crashed by 9535.45% in 2025.
  • 10x Genomics' Asset Writedowns and Impairment (Quarter) stood at $7.1 million in 2023, then crashed by 91.5% to $600000.0 in 2024, then grew by 16.67% to $700000.0 in 2025.
  • Its last three reported values are $700000.0 in Q3 2025, $114000.0 for Q1 2025, and $600000.0 during Q4 2024.